TABLE 1.
Baseline characteristics of the population in study
| Number of patients | 166 |
| Male | 108 (66%) |
| Age | 65.1 SD18.6 |
| Age at psoriasis diagnosis |
32.1 SD 16.6 |
| BMI |
27 SD 6 |
| Obese (BMI ≥ 30) | 36 (22%) |
| PsA | 23 (14%) |
| Difficult‐site involvement | 119 (73%) |
| Comorbidity | 108 (66%) |
| CV disease | 63 (28%) |
| DM II | 14 (8%) |
| Smokers | 63 (38%) |
| Ex‐Smokers | 40 (23%) |
| Non‐Smokers | 62 (39%) |
| Bio‐Naive | 69 (42%) |
| Previous biologic treatments | |
| Adalimumab | 35 (21%) |
| Etanercept | 12 (7%) |
| Infliximab | 12 (7%) |
| Certolizumab | 4 (2%) |
| Ustekinumab | 42 (25%) |
| Secukinumab | 27 (16%) |
| Ixekizumab | 34 (20%) |
| Brodalumab | 10 (6%) |
| Guselkumab | 9 (5%) |
| Tildrakizumab | 1 (0.6%) |
| Multifailure for biologics (≥4) | 12 (7%) |
| Previous non biologic systemic treatment | |
| Phototherapy | 27 (16%) |
| Methotrexate | 98 (59%) |
| Cyclosporine | 82 (49%) |
| Acitretin | 35 (21%) |
| Apremilast | 8 (5%) |
| Dimethyl fumarate | 2 (1%) |
| Baseline PASI | 12.5 SD 5.1 |
Abbreviations: BMI, body mass index; CV, cardiovascular; DM II, diabetes mellitus II; PASI, Psoriasis Area Severity Index; PSA, psoriatic arthritis; SD, standard deviation.